Compound
Retatrutide
The compound named in the current product listing.
NOVAPEP / Product record / Retatrutide
Exact report pendingResearch product / 01
A precise product record, not a generic product claim.
This page separates the listed presentation, current documentation state and research context so each can be reviewed on its own terms.
LY343794340 mg presentationLaboratory research listing
- Product
- Retatrutide
- Total strength
- 40 mg
- Presentation
- Lyophilised vial
- Batch
- See current record
- Documentation
- Exact-match only
- Regulatory status
- Investigational
Listing status
Investigational material. Not authorised as a UK medicine and not presented for human or veterinary use.
LABEL SPECIFICATION / 02
The presentation, without assumptions.
These fields describe the current listing. They are not independently verified results for identity, purity, content, sterility or quality.
Labelled amount
40 mg
Label information. A matching quantitative assay is required to verify content.
PACK CONTENTS
One vial
One labelled vial is included in the current presentation.
Listed state
Lyophilised
Physical description only; not evidence of identity or quality.
RESEARCH CLASSIFICATION
Investigational triple agonist
illy describes Retatrutide as acting at GIP, GLP-1 and glucagon receptors. Investigational status is not regulatory approval.
DEVELOPMENT IDENTIFIER
LY3437943
The development code associated with Retatrutide in sponsor research.
EVIDENCE BOUNDARIES / 05
What a report can-and cannot-show.
A laboratory result applies only to the sample, method and measurement described in the matching report.
A matching report may support
- Identity, when an appropriate identification method is reported for the matching sample and batch.
- Purity by the specific chromatographic method and calculation stated in the report.
- A content or mass result only when that measurement is explicitly included.
A report does not establish
- Clinical effectiveness, therapeutic benefit or fitness for personal use.
- Sterility, endotoxin or contaminant status unless those tests are separately reported.
- Regulatory approval or authorisation as a medicine in the United Kingdom.
Source register / 07
Verify the status at the primary source.
Regulatory status, sponsor information and batch analysis answer different questions. Each source is labelled so it cannot be mistaken for another kind of evidence.
UK authorisation and sale warning
MHRA · published 24 July 2026
Molecule and development status
Eli Lilly and Company · updated July 2026
Exact Retatrutide batch report
Not published in the current product record
Documentation process / 08
What a publishable batch record requires.
Four checks keep a laboratory document attached to the sample it actually describes—not to a similar-looking product page.
01
Match the full presentation
Confirm the compound, labelled amount, vial format and any sample description in the report.
02
Match one batch identifier
The identifier on the product record, pack and laboratory report must be the same.
03
Record method and scope
Name the laboratory, report number, test date, method, result and stated limitations.
04
Publish the complete original
Provide the full report file. A cropped image, badge or rewritten percentage is not a substitute.
Questions / 09
The questions a credible product record should answer.
Short answers on status, evidence and scope—without medical or administration guidance.
Is Retatrutide authorised for use or sale in the UK?
No. The MHRA states that retatrutide has not been authorised for use in the UK and that anyone selling a product claiming to contain it is doing so illegally.
When is a certificate shown as linked?
Only when the listed product, strength, presentation and batch match the report and the original file is available.
Does HPLC purity show peptide content?
Not necessarily. Chromatographic area purity and peptide content are different measurements. Review the method and reported result in the original file.
Does ‘research use only’ make the listing authorised?
No. The wording does not create a marketing authorisation, prove laboratory quality or change the MHRA’s stated position on retatrutide sales.
What does ‘exact report pending’ mean?
It means the product name, labelled amount, presentation, batch identifier, report number and original laboratory file have not all been published as one matching record. It does not imply a result.
Does this page provide dosing, injection or treatment advice?
No. It provides no medical, dosing, injection, administration, treatment or personal-use guidance.
THE JOURNAL
Method notes, assay results and what we publish alongside every batch.
What Is GHK-Cu? Copper Peptide Research Guide | NOVAPEP
GHK-Cu: What Is the Copper Peptide and Why Is It Studied? GHK-Cu is a naturally occurring copper-binding tripeptide complex that has been investigated for...
